Research programme: chlamydia vaccine - Sanofi-aventis
Latest Information Update: 16 Jul 2016
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chlamydial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chlamydial-infections in France (Parenteral, Injection)
- 22 Apr 2008 Preclinical trials in Chlamydial infections in France (Parenteral)